TC-2559 free base

TC-2559 free base 是一种 α4β2 烟碱型乙酰胆碱受体 (nAChR) 激动剂(EC50 为 0.18 μM),对 β4 亚基的 nAChR 基因型(α2β4、α4β4 和 α3β4 受体)激动效力较弱(EC50 在 10-30 μM 之间),能在体外增加大鼠腹侧被盖区 (VTA) 中的多巴胺细胞放电并增强 VTA 多巴胺能神经元的兴奋性和爆发性行为,还可通过抑制 STAT3 发挥抗炎作用、缓解小鼠的机械性异常疼痛并改善大鼠认知缺陷,因此可用于研究神经疼痛。
产品编号: MS-M55670 CAS No.: 189274-78-0 分子式: C12H18N2O 分子量: 206.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TC-2559 free base 是一种 α4β2 烟碱型乙酰胆碱受体 (nAChR) 激动剂(EC50 为 0.18 μM),对 β4 亚基的 nAChR 基因型(α2β4、α4β4 和 α3β4 受体)激动效力较弱(EC50 在 10-30 μM 之间),能在体外增加大鼠腹侧被盖区 (VTA) 中的多巴胺细胞放电并增强 VTA 多巴胺能神经元的兴奋性和爆发性行为,还可通过抑制 STAT3 发挥抗炎作用、缓解小鼠的机械性异常疼痛并改善大鼠认知缺陷,因此可用于研究神经疼痛。

生物实验数据

生物活性 TC-2559 free base is an α4β2 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 0.18 μM that shows weaker agonist potency at β4 subunit-containing nAChR genotypes (α2β4, α4β4, and α3β4 receptors) with EC50 values between 10-30 μM, increases dopamine cell firing in the rat ventral tegmental area (VTA) in vitro, enhances the excitability and bursting behavior of VTA dopaminergic neurons, exerts anti-inflammatory effects by inhibiting STAT3, alleviates mechanical allodynia in mice, and improves cognitive deficits in rats, and can therefore be used for the study of neuropathic pain.
体外研究
(In Vitro)

TC-2559 free base (free base) 能有效与 [3H]-莫可托品结合 (Ki = 5 nM)。
TC-2559 free base (0-100 nM) 能够增强大鼠纹状体突触小体多巴胺 (EC50 = 203 nM, E = 97%) 和大脑丘脑突触小体 Rb 蛋白的释放 (EC50 = 367 nM, E = 107%),并且在 1mM 浓度下对 TE671/RD 细胞和 PC12 细胞无活性。
TC-2559 free base (10 μM, 2 h) 能显著降低胎鼠脑细胞中的神经元死亡。
TC-2559 free base (200-500 μM, 3-6 h) 能够抑制小鼠巨噬细胞中细胞因子配体 3 (CCL3) 和白细胞介素 1b (IL-1b) 的上调表达。
TC-2559 free base (500 μM, 1-6 h) 能够抑制小鼠巨噬细胞中信号转导及转录激活因子 3 (pSTAT3) 的磷酸化。
TC-2559 free base (0.5 mM, 24 h) 能够抑制小鼠腹腔巨噬细胞 PSL 处理后受损的 SCN 中白细胞介素-1β (IL-1β) 的过度表达。
TC-2559 free base 对 β4 亚基的 nAChR 基因型 (α2β4、α4β4 和 α3β4 受体) 展示了较弱的激动效力,其 EC50 分别为 14、12.5 and >30 μM。

RT-PCR

Cell Line: Mouse macrophage J774A.1 cells
Concentration: 20-500 μM with LPS (MS-X54539)
Incubation Time: 3 and 6 h
Result: Suppressed the mRNA expressions of CCL3 and IL-1b.

Western Blot Analysis

Cell Line: Mouse macrophage J774A.1 cells
Concentration: 500 μM with LPS
Incubation Time: 1,3 and 6 h
Result: Inhibited the upregulation of pSTAT3 at 6 h.
Had no effect on pp65 expression at 1 and 6 h.
体内研究
(In Vivo)

TC-2559 free base (free base) (0.124-2.063 mg/kg, s.c., 单次剂量) 能够剂量依赖性地逆转由胆碱能阻断所导致的大鼠记忆障碍。
HC-2559 (0.124-1.238 mg/kg, s.c., 单次给药或连续 5 天给药) 能显著减少工作记忆错误,并持续改善工作记忆。
HC-2559 (0.206-2.063 mg/kg, s.c., 单次给药或连续 14 天给药) 单次给药时会导致运动抑制,而连续给药则不会引发行为耐受性。
TC-2559 free base (0.021-1.32 mg/kg, i.v., 累计给药或单次给药) 通过 α4β2 样烟碱型受体激活伏隔核的多巴胺神经元。
TC-2559 free base (0.47-4.70 mg/kg, s.c. 或 20 nmol, 神经周围注射, 3 天) 显著缓解了小鼠行为模型中的机械性异常疼痛。
TC-2559 free base (20 nmol, 神经周围注射, 3 天) 能够抑制由小鼠周围神经损伤所引发的 SDH 中的微胶质细胞活化。

Animal Model: Attenuation of scopolamine-induced amnesia established in male Sprague-Dawley rats (200-350 g)
Dosage: 0.124, 0.206, 0.619, 1.238 and 2.063 mg/kg (0.6, 1, 3, 6 and 10 μmol/mg)
Administration: Subcutaneous Injections (s.c.), single dose
Result: Attenuated scopolamine-induced decrease of avoidance latencies of 21.5 s at doses of 3 and 6 μmol/kg.
Exhibited the median step-through latencies of 88.7 and 105.7 s for 3 and 6 μmol/kg, respectively.
Animal Model: Radial-arm maze performance model established in male Sprague-Dawley rats (200-350 g)
Dosage: 0.124, 0.206, 0.619 and 1.238 mg/kg (0.6, 1, 3 and 6 μmol/mg)
Administration: Subcutaneous Injections (s.c.), single dose or for 5 days
Result: Significantly reduced the number of working memory errors at 3 and 10 μmol/kg in Day 1.
Significantly reduced working memory errors following 6 days of repeated administration at 1, 3, and 6 μmol/kg.
Animal Model: Locomotor activity model established in male Sprague-Dawley rats (200-350 g)
Dosage: 0.124, 0.412 and 2.063 mg/kg for acute administration and 0.721 mg/kg for repeated administration
Administration: Subcutaneous Injections (s.c.), single dose or once daily or for 14 days
Result: Resulted in significant reductions in horizontal counts at the 30-min time point.
Resulted in a dose-dependent monophasic change in locomotor behavior with a sustained hypolocomotion at 60 min for the 0.206 mg/kg dose.
No apparent sensitization developed following repeated administration.
Animal Model: Electrophysiological model established in male Sprague-Dawley rats (260-350 g)
Dosage: 0.021-1.32 mg/kg or 0.66 and 1.32 mg/kg
Administration: Intravenous injection (i.v.), cumulative doses or single dose
Result: Increased the discharge frequency by 185%-206%.
Increased the peak discharge frequency to 141% at 0.66 mg/kg.
induced bursting in one of two nonbursting VTA DA neurones tested.
Evoked a significant increase in both spontaneous and burst firing for up to 15 min of the testing period at 1.32 mg/kg.
Were blocked by DHbE, but not by MLA.
Animal Model: Behavioral testing in male ICR mice aged 4 to 5 weeks
Dosage: 0.470, 1.41 and 4.70 mg/kg (2.28, 6.84 and 22.8 μmol/kg) (s.c.) or 20 nmol (p.n.)
Administration: Subcutaneous Injections (s.c.) or perineural Injections (p.n.) for 3 days
Result: Significantly increase the mechanical pain threshold at 22.8 μmol/kg during either the early (days 0–3) or middle/late (days 7–10).
Improved mechanical allodynia with Sazetidine A (MS-A26915) with p.n. admisitraion during the early or middle phase.
Relieved mechanical allodynia with p.n. during the late (days 21-24) phase.
Animal Model: Microglial activation assay in male ICR mice aged 4 to 5 weeks
Dosage: 20 nmol
Administration: Perineural Injections (p.n.) for 3 days
Result: Suppressed microglial activation in the SDH evaluated by Iba1 expression.
Significantly down-regulate inflammatory markers such as CD68, IRF5, and IL-1β.

化学信息

分子量 206.28
分子式 C12H18N2O
CAS No. 189274-78-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础